Compare PXED & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | IMTX |
|---|---|---|
| Founded | 1976 | N/A |
| Country | | |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | PXED | IMTX |
|---|---|---|
| Price | $30.00 | $9.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $44.29 | $19.25 |
| AVG Volume (30 Days) | 80.6K | ★ 360.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $4.75 | $19.39 |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $3.30 |
| 52 Week High | $47.08 | $12.41 |
| Indicator | PXED | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 51.18 |
| Support Level | $26.69 | $9.67 |
| Resistance Level | $29.25 | $10.42 |
| Average True Range (ATR) | 1.67 | 0.68 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 67.71 | 68.50 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.